It is a long established fact that a reader of a page when looking at its layout.

    SmartLung Dx*

    A diagnostic test identifying benign lung nodules without biopsy.

    • It is estimated that there are tens of millions of patients in the total addressable global market.
    • Current standard of care is an invasive lung biopsy, or watch-and-wait with multiple scans.
    • SmartLung Dx is a non-invasive blood test that identifies lung nodules that are likely benign, enabling patients to avoid potentially risky invasive biopsy procedures.
    • We believe this test will help minimize hospitalizations from lung biopsy complications.
    *In development